Accord Healthcare to create 500 jobs at Fawdon Factory

Accord Healthcare to create 500 jobs at Fawdon Factory

Accord Healthcare has held the official opening of its Fawdon factory, which will employ up to 500 members of staff, predominately from the local community.

The 22-acre factory, was formally opened by Labour MP for Newcastle upon Tyne North, Catherine McKinnell, at an event which was attended by representatives from Newcastle City Council, local business groups and government bodies.

Catherine McKinnell MP, said: “I am so pleased to see this site back in productive use, and creating good, skilled jobs in our local economy. Accord’s investment in its Fawdon plant is a real vote of confidence in Newcastle by its owners, and I am delighted that they have such big and exciting plans for the future. Our city has a proud history of innovation and I’m looking forward to supporting Accord Healthcare to play an important part in that.”

Opening with over sixty employees already in place at the Fawdon site, Accord hopes to double this number in the coming months, with more jobs planned when the factory production expands. It is currently recruiting for a variety of roles from operational positions to scientists to factory floor.

Along with sites in Harrow, Barnstaple, Haverhill and Didcot, Fawdon will play a key part in supporting Accord’s as a fast-growing pharmaceutical company.  With dedicated investment and a five-year growth strategy behind it, Fawdon will be the first Accord site to produce generic effervescent medicines and become its regional centre for excellence for effervescent tablets and other types of medicine.

The Fawdon opening will also significantly strengthen Accord’s UK distribution network and offshore activity exporting to over 35 countries across Europe and beyond.

Dr James Burt, executive vice president, Europe & MENA, Accord Healthcare, said: “Fawdon will play a vital role in strengthening our manufacturing network, supported by our parent company Intas and our other UK sites.

“After seeing many domestic pharmaceutical manufacturing sites close, with production redirected overseas, this opening marks a vote of confidence in the UK’s attractiveness for high tech pharmaceutical manufacturing. We are committed to further strategic investment to support the site’s growth, adding value to the local economy in terms of jobs and exports, as well as furthering patient access to affordable medicines in both the UK and beyond.”